The Tumor-Specific Expression of L1 Retrotransposons Independently Correlates with Time to Relapse in Hormone-Negative Breast Cancer Patients
暂无分享,去创建一个
A. Sapino | S. Bellomo | T. Venesio | F. Montemurro | S. Giordano | C. Marchiò | U. Miglio | A. Petrelli | E. Cascardi | E. Berrino | C. Debernardi | A. Bragoni | Annalisa Petrelli | Alberto Bragoni
[1] L. Ding,et al. LINE-1 expression in cancer correlates with p53 mutation, copy number alteration, and S phase checkpoint , 2022, Proceedings of the National Academy of Sciences.
[2] V. Ranzani,et al. LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion , 2022, Nature Genetics.
[3] Yujie Sun,et al. Paclitaxel-induced stress granules increase LINE-1 mRNA stability to promote drug resistance in breast cancer cells , 2021, Journal of biomedical research.
[4] A. Sapino,et al. Evaluation of global and intragenic hypomethylation in colorectal adenomas improves patient stratification and colorectal cancer risk prediction , 2021, Clinical epigenetics.
[5] Anh Nguyen-Duc,et al. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study , 2021, Journal of the National Cancer Institute.
[6] Ahn, Jin Hee,et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial , 2020, The Lancet.
[7] P. Provero,et al. MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer , 2020, ESMO Open.
[8] I. Mamedov,et al. Aberrant Methylation of LINE-1 Transposable Elements: A Search for Cancer Biomarkers , 2020, Cells.
[9] Rui Zhang,et al. New Understanding of the Relevant Role of LINE-1 Retrotransposition in Human Disease and Immune Modulation , 2020, Frontiers in Cell and Developmental Biology.
[10] J. Dahlstrom,et al. Efavirenz as a potential drug for the treatment of triple-negative breast cancers , 2020, Clinical and Translational Oncology.
[11] J. Deleuze,et al. Tumor DNA hypomethylation of LINE-1 is associated with low tumor grade of breast cancer in Tunisian patients. , 2020, Oncology letters.
[12] G. Faulkner,et al. Nanopore sequencing enables comprehensive transposable element epigenomic profiling , 2020, bioRxiv.
[13] A. Sapino,et al. The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas , 2020, Pathobiology.
[14] P. Mandal,et al. LINE-1 retrotransposon encoded ORF1p expression and promoter methylation in oral squamous cell carcinoma: a pilot study. , 2020, Cancer genetics.
[15] David T. W. Jones,et al. Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition , 2020, Nature Genetics.
[16] S. Devine,et al. Aberrantly High Levels of Somatic LINE-1 Expression and Retrotransposition in Human Neurological Disorders , 2020, Frontiers in Genetics.
[17] H. Krause,et al. Long Noncoding RNAs and Repetitive Elements: Junk or Intimate Evolutionary Partners? , 2019, Trends in genetics : TIG.
[18] Sung-Bae Kim,et al. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] L. Thuler,et al. Impact of Number of Positive Lymph Nodes and Lymph Node Ratio on Survival of Women with Node-Positive Breast Cancer. , 2019, European journal of breast health.
[20] S. O'Reilly,et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. , 2019, The New England journal of medicine.
[21] I. Shih,et al. Long Interspersed Nuclear Element 1 Retrotransposons Become Deregulated during the Development of Ovarian Cancer Precursor Lesions. , 2019, The American journal of pathology.
[22] X. Guan,et al. Different Triple-Negative Breast Cancer Tumor Cell Lysates (TCLs) Induce Discrepant Anti-Tumor Immunity by PD1/PDL-1 Interaction , 2019, Medical science monitor : international medical journal of experimental and clinical research.
[23] A. Sapino,et al. The expression of LINE1‐MET chimeric transcript identifies a subgroup of aggressive breast cancers , 2018, International journal of cancer.
[24] A. Vincent-Salomon,et al. The Dilemma of HER2 Double-equivocal Breast Carcinomas , 2018, The American journal of surgical pathology.
[25] J. Boeke,et al. Cycling to Maintain and Improve Fitness: Line-1 Modes of Nuclear Entrance and Retrotransposition , 2018, SLAS discovery : advancing life sciences R & D.
[26] N. Rodić. LINE-1 activity and regulation in cancer. , 2018, Frontiers in bioscience.
[27] Sean Ferree,et al. PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. V. Moran,et al. Mobile DNA in Health and Disease , 2017, The New England journal of medicine.
[29] K. Burns. Transposable elements in cancer , 2017, Nature Reviews Cancer.
[30] Frederick S. Vizeacoumar,et al. Molecular characterization of breast cancer cell lines through multiple omic approaches , 2017, Breast Cancer Research.
[31] K. Burns,et al. The Human Long Interspersed Element-1 Retrotransposon: An Emerging Biomarker of Neoplasia. , 2017, Clinical chemistry.
[32] R. Meehan,et al. Decoupling of DNA methylation and activity of intergenic LINE-1 promoters in colorectal cancer , 2017, Epigenetics.
[33] A. Sapino,et al. Oxidative DNA damage induces hypomethylation in a compromised base excision repair colorectal tumourigenesis , 2017, British Journal of Cancer.
[34] Fang Yang,et al. Multiple LINEs of retrotransposon silencing mechanisms in the mammalian germline. , 2016, Seminars in cell & developmental biology.
[35] Jacqueline R. Kemp,et al. Crossing the LINE Toward Genomic Instability: LINE-1 Retrotransposition in Cancer , 2015, Front. Chem..
[36] E. Mardis,et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay , 2015, BMC Medical Genomics.
[37] J Cuzick,et al. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] J. V. Moran,et al. The Influence of LINE-1 and SINE Retrotransposons on Mammalian Genomes , 2015, Microbiology spectrum.
[39] T. Nielsen,et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] Sean Ferree,et al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens , 2014, BMC Cancer.
[41] J. Dahlstrom,et al. Inhibition of LINE-1 retrotransposon-encoded reverse transcriptase modulates the expression of cell differentiation genes in breast cancer cells , 2013, Breast Cancer Research and Treatment.
[42] J. Dahlstrom,et al. Prognostic value of LINE-1 retrotransposon expression and its subcellular localization in breast cancer , 2012, Breast Cancer Research and Treatment.
[43] Jane E Dahlstrom,et al. Naturally occurring endo-siRNA silences LINE-1 retrotransposons in human cells through DNA methylation , 2012, Epigenetics.
[44] H. Putter,et al. Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study , 2012, Breast Cancer Research and Treatment.
[45] N. Henry,et al. Cancer biomarkers , 2012, Molecular oncology.
[46] J. V. Moran,et al. LINE-1 elements in structural variation and disease. , 2011, Annual review of genomics and human genetics.
[47] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] O. J. Semmes,et al. Human LINE-1 retrotransposon induces DNA damage and apoptosis in cancer cells , 2006, Cancer Cell International.
[49] Thomas Dandekar,et al. L1Base: from functional annotation to prediction of active LINE-1 elements , 2004, Nucleic Acids Res..
[50] Apiwat Mutirangura,et al. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis , 2004, Oncogene.
[51] M. Noguchi,et al. Prognosis of Node-Positive Breast Cancer Patients Who Underwent Parasternal Lymph Node Biopsy During Surgery Followed by Doxorubicin- or Mitoxantrone-Containing Adjuvant Chemotherapy , 2000, Journal of chemotherapy.
[52] K. Kinzler,et al. Disruption of the APC gene by a retrotransposal insertion of L1 sequence in a colon cancer. , 1992, Cancer research.
[53] C. Carter,et al. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989, Cancer.
[54] J. Spandorfer,et al. Insertional mutagenesis of the myc locus by a LINE-1 sequence in a human breast carcinoma , 1988, Nature.
[55] M. Bergmann,et al. A role of LINE-1 in telomere regulation. , 2018, Frontiers in bioscience.
[56] Kyoung-Mee Kim,et al. Deamination Effects in Formalin-Fixed, Paraffin-Embedded Tissue Samples in the Era of Precision Medicine. , 2017, The Journal of molecular diagnostics : JMD.
[57] E. Gelmann,et al. Differentiation state and invasiveness of human breast cancer cell lines , 2004, Breast Cancer Research and Treatment.